OKYO Pharma (Nasdaq: OKYO) to present and plan Phase 3 NCP trial

Rhea-AI Filing Summary

OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, announced that its CEO Robert J. Dempsey and CMO Flavio Mantelli will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 12:30 PM.

The company also plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain. OKYO states that this information is incorporated by reference into its Registration Statement on Form F-3 (Reg. No. 333-293145).

Filing Explained

This Form 6-K furnishes the presentation announcement as Exhibit 99.1 and states that the exhibit is not deemed filed for Section 18 purposes, while the report itself is incorporated by reference into the company’s Form F-3; the added effect is legal treatment rather than a change to the disclosed presentation plans.

Key Figures

Conference presentation date and time: Wednesday, July 22, 12:30 PM Planned Phase 3 trial enrollment: approximately 111 patients Form F-3 registration number: 333-293145

3 metrics

Conference presentation date and time Wednesday, July 22, 12:30 PM H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Planned Phase 3 trial enrollment approximately 111 patients Global Phase 3 pivotal clinical trial for neuropathic corneal pain

Form F-3 registration number 333-293145 Registration Statement on Form F-3 (Reg. No. 333-293145)

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"developing innovative therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"developing innovative therapies for the treatment of NCP and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

Registration Statement on Form F-3 regulatory

"incorporated by reference into the Company’s Registration Statement on Form F-3"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/21/2026 - 09:00 AM Accepted by SEC EDGAR 07/21/2026 - 09:00 AM Learn about SEC filing dates

FAQ

What did OKYO (OKYO) announce about the H.C. Wainwright ophthalmology conference?

OKYO Pharma announced that its leadership will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference. CEO Robert J. Dempsey and CMO Flavio Mantelli are scheduled to speak on Wednesday, July 22, 2026, at 12:30 PM in a fully virtual format.

What Phase 3 clinical trial is OKYO (OKYO) planning for urcosimod?

OKYO plans a global Phase 3 pivotal clinical trial of urcosimod for neuropathic corneal pain (NCP). The study, expected to start in the second half of this year, is designed to enroll approximately 111 patients using a single-dose regimen of the investigational therapy.

Which diseases is OKYO (OKYO) targeting with its therapies?

OKYO is developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. The company describes itself as a clinical-stage biopharmaceutical business with ordinary shares listed on the Nasdaq Capital Market, focused on innovative ophthalmic treatments.

Who will represent OKYO (OKYO) at the ophthalmology conference presentation?

OKYO will be represented by Robert J. Dempsey, Chief Executive Officer, and Flavio Mantelli, MD, PhD, Chief Medical Officer. They are scheduled to present the company’s ophthalmology program during the virtual conference session on July 22, 2026, at 12:30 PM.

How can investors and analysts obtain more information about OKYO (OKYO)?

Further information is available on the company website at www.okyopharma.com. Investor and business development inquiries can be directed to Paul Spencer at +44 (0) 207 495 2379 or via email at info@okyopharma.com for additional details and materials.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 21, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 21, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 21, 2026

4

Exhibit 99.1

OKYO Pharma to Present at the H.C. Wainwright 6^th Annual Ophthalmology Virtual Conference

London and New York, NY, July 21, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6^th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

Details of the event are as follows:

Presenter: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: Wednesday, July 22, 12:30 PM ET

Location: Virtual

Register to Attend: H.C. Wainwright Registration

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 8.8 KB
• EX-99 GRAPHIC 4.4 KB